2. Academic Validation
  3. Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study

Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study

  • PLoS One. 2014 Feb 4;9(2):e87585. doi: 10.1371/journal.pone.0087585.
Cheryl A London 1,  Luis Feo Bernabe 1,  Sandra Barnard 1,  William C Kisseberth 1,  Antonella Borgatti 2,  Mike Henson 2,  Heather Wilson 3,  Kiersten Jensen 2,  Daisuke Ito 2,  Jaime F Modiano 2,  Misty D Bear 1,  Michael L Pennell 4,  Jean-Richard Saint-Martin 5,  Dilara McCauley 5,  Michael Kauffman 5,  Sharon Shacham 5
Affiliations

Affiliations

  • 1 Departments of Veterinary Biosciences and Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio, United States of America.
  • 2 Department of Veterinary Clinical Sciences and Masonic Cancer Center, University of Minnesota, Minneapolis/St. Paul, Minnesota, United States of America.
  • 3 Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, United States of America.
  • 4 Division of Biostatistics, College of Public Health, The Ohio State University, Columbus, Ohio, United States of America.
  • 5 Karyopharm Therapeutics, Natick, Massachusetts, United States of America.
PMID: 24503695 DOI: 10.1371/journal.pone.0087585
Abstract

Background: The purpose of this study was to evaluate the activity of Selective Inhibitors of Nuclear Export (SINE) compounds that inhibit the function of the nuclear export protein Exportin 1 (XPO1/CRM1) against canine tumor cell lines and perform a Phase I clinical trial of KPT-335 in dogs with spontaneous Cancer to provide a preliminary assessment of biologic activity and tolerability.

Methods and findings: Canine tumor cell lines derived from non-Hodgkin lymphoma (NHL), mast cell tumor, melanoma and osteosarcoma exhibited growth inhibition and Apoptosis in response to nanomolar concentrations of SINE compounds; NHL cells were particularly sensitive with IC50 concentrations ranging from 2-42 nM. A Phase I clinical trial of KPT-335 was performed in 17 dogs with NHL (naive or relapsed), mast cell tumor or osteosarcoma. The maximum tolerated dose was 1.75 mg/kg given orally twice/week (Monday/Thursday) although biologic activity was observed at 1 mg/kg. Clinical benefit (CB) including partial response to therapy (PR, n = 2) and stable disease (SD, n = 7) was observed in 9/14 dogs with NHL with a median time to progression (TTP) for responders of 66 days (range 35-256 days). A dose expansion study was performed in 6 dogs with NHL given 1.5 mg/kg KPT-335 Monday/Wednesday/Friday; CB was observed in 4/6 dogs with a median TTP for responders of 83 days (range 35-354 days). Toxicities were primarily gastrointestinal consisting of anorexia, weight loss, vomiting and diarrhea and were manageable with supportive care, dose modulation and administration of low dose prednisone; hepatotoxicity, anorexia and weight loss were the dose limiting toxicities.

Conclusions: This study provides evidence that the novel orally bioavailable XPO1 inhibitor KPT-335 is safe and exhibits activity in a relevant, spontaneous large animal model of Cancer. Data from this study provides critical new information that lays the groundwork for evaluation of SINE compounds in human Cancer.

Figures
Products